Siremadlin succinate
Based on 11 publication(s) in Google Scholar
Siremadlin (NVP-HDM201) succinate is an MDM2 inhibitor and cell cycle regulator. Siremadlin succinate blocks the p53-binding pocket of MDM2, inhibits MDM2-mediated ubiquitination and degradation of p53, thereby activating the p53 pathway in p53 wild-type cells. Siremadlin succinate can be used in the research of cutaneous melanoma.
For research use only. We do not sell to patients.
- CAS No.: 1638193-48-2
- Formula: C30H30Cl2N6O8
- Molecular Weight:673.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Siremadlin succinate
More- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- Oncogenesis. 2022 Jul 2;11(1):37. [Abstract]
- Cells. 2026 Mar 5;15(5):473. [Abstract]
- Int J Mol Sci. 2022 Oct 8;23(19):11939. [Abstract]
- Cell Rep Methods. 2025 Oct 17:101207. [Abstract]
- Cancers (Basel). 2022 Oct 19;14(20):5127. [Abstract]
- iScience. 2024 May 6;27(6):109862. [Abstract]
- Cancer Res Commun. 2026 Mar 1;6(3):616-629. [Abstract]
- Carcinogenesis. 2024 Jun 13:bgae040. [Abstract]
- bioRxiv. 2025 Nov 30:2025.11.26.690792. [Abstract]
- SSRN. 2023 Oct 9.
Biological Activity
Siremadlin (NVP-HDM201) succinate (72 h) had its growth-inhibitory activity potentiated by 2.5 μM GSK2830371 in p53 wild-type (A375, WM35, C8161) but not p53 mutant (WM164, WM35-R, CHL-1) cutaneous melanoma cell lines by decreasing the GI50 of Siremadlin succinate[1].
Siremadlin succinate (72 h) had its cytotoxic activity potentiated by 2.5 μM GSK2830371 in p53 wild-type (A375, WM35, C8161) but not p53 mutant (WM164, WM35-R, CHL-1) cutaneous melanoma cell lines by decreasing the LC50 of Siremadlin (succinate)[1].
Siremadlin succinate(0.2 μM; 6 h, 24 h) in combination with 2.5 μM GSK2830371 enhances p53 stabilisation, phosphorylation, acetylation, and transcriptional activity in p53 wild-type (A375, C8161) cutaneous melanoma cell lines[1].
Siremadlin succinate (0.2 μM; 24 h) in combination with 2.5 μM GSK2830371 enhances p53-dependent cell cycle changes and apoptosis in p53 wild-type (A375, WM35, C8161) but not p53 mutant (WM35-R) cutaneous melanoma cell lines[1].
Siremadlin succinate had its activity potentiation by 2.5 μM GSK2830371 in p53 wild-type (A375, WM35) cutaneous melanoma cell lines strictly p53-dependent[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:p53 wild-type (A375, WM35, C8161); p53 mutant (WM164, WM35-R, CHL-1) cutaneous melanoma cell lines
-
Concentration:2.5 μM GSK2830371 (co-treatment)
-
Incubation Time:72 h
-
Result:Significantly decreased the GI50 of HDM201 in p53 wild-type cutaneous melanoma cell lines compared to treatment with Siremadlin succinate alone.
Showed no potentiation in p53 mutant cell lines.\nSignificantly decreased the LC50 of siremadlin succinate in A375 and C8161 cells, and showed a similar trend in WM35 cells compared to treatment with Siremadlin (succinate) alone.
Showed no potentiation in p53 mutant cell lines.
Chemical Information
-
CAS No. 1638193-48-2
-
Molecular Weight 673.50
-
Formula C30H30Cl2N6O8
-
SMILES
OC(CCC(O)=O)=O.CC(N1C([C@H](C2=CC=C(C=C2)Cl)N3C4=CC(Cl)=CN(C)C4=O)=C(N=C1C5=CN=C(OC)N=C5OC)C3=O)C
-
Synonyms
NVP-HDM201 succinate; HDM201 succinate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Oncogenesis
LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression. [Abstract]2022 Jul 2;11(1):37. PMID: 35780125 -
Cells
PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells. [Abstract]2026 Mar 5;15(5):473. PMID: 41827906 -
Int J Mol Sci
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II. [Abstract]2022 Oct 8;23(19):11939. PMID: 36233247 -
Cell Rep Methods
2025 Oct 17:101207. PMID: 41109218 -
Cancers (Basel)
Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]2022 Oct 19;14(20):5127. PMID: 36291909 -
iScience
MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors. [Abstract]2024 May 6;27(6):109862. PMID: 38784022 -
Cancer Res Commun
Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. [Abstract]2026 Mar 1;6(3):616-629. PMID: 41747217 -
Carcinogenesis
BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer. [Abstract]2024 Jun 13:bgae040. PMID: 38868979 -
bioRxiv
Uncovering senescent fibroblast heterogeneity connects DNA damage response to idiopathic pulmonary fibrosis. [Abstract]2025 Nov 30:2025.11.26.690792. PMID: 41394576 -
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz